



2024/2025

Annual Report



ACKNOWLEDGEMENT OF COUNTRY

In the spirit of reconciliation, FOP Australia acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community.

We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples.

In recognition that we operate in Australia & New Zealand, FOP Australia acknowledges Māori as tangata whenua and Treaty of Waitangi partners in Aotearoa New Zealand.



Contents

Overview of FOP Australia	3
Organisational Aims	3
2024-2025 Board of Directors	4
Chairpersons Report	4
Treasurer’s Report	6
IFOPA International Presidents Council Report	7
Medical Report	8
Acknowledgements and Contact Details	10
Community Acknowledgements	10
Fundraiser Acknowledgements	10
FOP Australia: How you can help	10
FOP Australia: Contact Us	11
Appendix 1: Financial Statements	12
Statement of Profit or Loss and other comprehensive income for the year ending 30th June 2025	12
Statement of Financial Position	13
Statement of Cash Flows	14
Appendix 2: Notes to Financial Statements	15
Appendix 3: Directors Declaration	17

Cover photos:

- Adelaide Oval, lit up Green for FOP Awareness Day 23 April 2025
- Zach Armstrong celebrating his Year 12 Graduation
- Michael Robinson, Anne Roberts, Ruth Robinson and Phillip Robinson.
- Jack Fegan and Jacqui Scruby raising awareness for Rare Diseases day
- Outgoing Board Director, Jo McAlpine

Overview of FOP Australia

FOP Australia was established in 2015, with the first Annual General Meeting held in Brisbane in May that year. FOP Australia is registered with the Australian Charities and Not-for-profits Commission (ACNC) as a charity with Deductible Gift Recipient (DGR) status through the Australian Tax Office. This organisation is a company limited by guarantee; we have a board of directors and are accountable to our members. We have no paid employees and run purely through volunteers.

Through links with the [International FOP Association \(IFOPA\)](#), we aim to improve the lives of individuals and families affected by FOP by:

- Raising awareness of FOP
- Providing a support network for families and individuals with FOP
- Furthering research towards treatment and a cure

With the FOP research effort entering the clinical trial phase, in late 2018 the board mapped out an [Advocacy Strategy](#) for the charity to guide future strategic planning. You can read more about the development of the strategy [here](#).

In working towards these goals, we are inspired by the work of the international FOP community, and are so grateful for the support of FOP champions.

Organisational Aims

Advocacy

Advocate for people with FOP in Australia and New Zealand to have access to any effective FOP therapies, including subsidised funding of therapies.

Fundraising

Provide a significant proportion of our fundraising to advances in research into treatments and/or a cure for FOP.

Build and Maintaining links with Medical Community

Build and maintain links with the medical community, including clinicians in Australia and New Zealand and internationally to understand new developments in medical research and its potential application to people with FOP.

Build and Maintaining strong links with FOP Research

Build and maintain links with the medical community, including clinicians in Australia and New Zealand and internationally to understand new developments in medical research and its potential application to people with FOP.

Build and Maintaining Strong Links with the International Community

Build and maintain strong links with those undertaking FOP research, including academic centres and pharmaceutical companies.

Establishing and Improving the function of FOP Australia

To establish and improve the function of FOP Australia as a representative and supportive organisation for the FOP community of Australia and New Zealand.

2024-2025 Board of Directors

Talia Wilson (Chairperson)

Jo McAlpine

Brooke Scott

Lydia Scott (Treasurer)

Lauren Gibson (Secretary)

Chairpersons Report

Chairperson's Report – FOP Australia AGM 2025

This has been a year of steady progress and growing momentum for FOP Australia, marked by meaningful advocacy efforts, strengthened relationships across the health and rare disease sectors, and continued support for individuals and families living with Fibrodysplasia Ossificans Progressiva. While our community remains small, our voice is growing stronger — driven by the dedication of those who contribute their time, expertise, and lived experience to advance awareness, access, and support.

Thank you

Firstly, I would like to acknowledge the immense contributions of Jo McAlpine, who is stepping down from the Board after several years of dedicated service. Jo has been an invaluable advocate and contributor and a deeply valued member of our team. Her wisdom, insight, and compassion have helped guide FOP Australia through key moments of growth and transition, and her ability to lead with both heart and purpose has left a lasting imprint on our organisation. It has been an absolute pleasure to work alongside Jo, and while we are sad to see her step back from the Board, we are excited to see what this next chapter holds for her. We thank Jo from the bottom of our hearts for everything she has brought to our community and look forward to staying closely connected as she embarks on new adventures in her personal life.

Community Impact

This year's fundraising efforts have once again showcased the creativity, generosity, and deep commitment of the FOP Australia community. Standout contributions included the beautiful fundraising calendars created by Jack and the Fegan family, which feature Jack's incredible photography and are a true celebration of talent and generosity, and the meaningful donations made by the Robinson and Roberts families in memory of Ruth Robinson, mother of Chris, who lived with FOP. These special initiatives — alongside ongoing fundraising efforts like sock sales and other community-led activities — reflect the diverse and passionate ways our supporters continue to contribute. We are sincerely grateful to everyone who has donated, organised, or supported fundraising activities throughout the year.

In addition to fundraising, one particularly powerful awareness moment this year was the lighting of the Adelaide Oval in green for FOP Awareness Day. This initiative was led by Board Member Brooke Scott, who brings both lived experience and deep understanding of the challenges that come with FOP. Seeing such an iconic Australian landmark illuminated in support of our community was a truly special moment — a bold and visible expression of solidarity on one of the most important days in our calendar.

Advocacy

February provided valuable opportunities to raise awareness and strengthen connections at a national level. I was proud to represent FOP Australia at two key events in Canberra this year: the Rare Disease Day Parliamentary Event, hosted by Rare Voices Australia at Parliament House, and the Australian Patient

Advocacy Alliance (APAA) Summit the following day. These events brought together leaders across the political spectrum and the rare disease sector to discuss health equity & effective advocacy, stakeholder engagement, and health literacy, particularly in the context of disability and rare disease.

While in Canberra, I met with several Members of Parliament to speak about FOP and the real-life challenges faced by individuals, families, and carers. These were positive and constructive conversations, with MPs showing genuine interest in the families within their electorates and a willingness to assist in the future. These moments of visibility are crucial in building relationships that may prove vital when future advocacy needs arise.

A major focus of our advocacy this year has been the continued journey toward listing Palovarotene — the first approved treatment for FOP in Australia, on the Pharmaceutical Benefits Scheme (PBS). Following its approval by the Therapeutic Goods Administration (TGA), palovarotene was reviewed by the Pharmaceutical Benefits Advisory Committee (PBAC) in November 2024 and was formally recommended for listing. While PBS access is still pending, this recommendation represents a major milestone for our community. For a more detailed overview of the PBAC process and its implications, please refer to the medical report later in this Annual Report.

Our submission to the PBAC was greatly strengthened by the powerful contributions of the FOP community — thank you to everyone who was able to share their story. We are especially grateful to Lydia Scott, whose time, care and thoughtfulness in gathering personal stories gave voice to our collective experience. This was a considerable undertaking and we are immensely proud of Lydia's endless time commitment and compassion in pulling together such an outstanding submission.

Following the PBAC process, I was invited to participate in a small roundtable discussion alongside other patient organisations. This provided an opportunity to share our submission experience, hear from others facing similar challenges, and contribute to a broader conversation about how the PBAC process might be improved for rare disease communities. It was encouraging to see a shared commitment to making this system more accessible and responsive for all.

What's to come

A significant milestone for our organisation this year has been the immense task of planning our community's 2025 FOP Australia Conference — now just weeks away. This event will bring together individuals living with FOP, along with their families, friends, and supporters. It has been nearly a decade since our last in-person gathering, and we are especially excited to be hosting this event in what marks FOP Australia's 10-year anniversary - a moment to reflect on our journey, reconnect with one another, and renew our shared purpose.

While our community remains small, it is strong, resilient and deeply connected. We are thrilled to be welcoming both familiar faces and those who have joined us in more recent years. This conference would not be possible without the dedication of our planning committee, and I would like to thank Coralie, Lyn, Brooke and Lydia for their tremendous effort in working alongside me to bring this event to fruition. We've also continued our commitment to offering practical support through the Oliver Collins Education Grant and the FOP Australia Support Grant, which remain available to people living with FOP — or their carers — in both Australia and New Zealand. These supports will continue into the foreseeable future. Looking ahead, our focus on research and advocacy also continues to grow. As detailed in the financial report, FOP Australia has successfully secured a grant to support a new research project aimed at better understanding the needs of people living with FOP in our region. The insights we gain will help inform future regulatory submissions and ensure that the voices and perspectives of our community remain central to healthcare decisions.

In Closing

As we look ahead with hope and determination, I want to take a moment to express my deepest thanks to Brooke, Lydia, Jo and Lauren as well as the broader community, for your patience, support, and understanding during what has been a profoundly difficult and personal time for myself and my family.

While this year has brought steady momentum in advocacy, support, and future planning, it has also been a time of deep reflection following the loss of my beautiful Tyson. I am especially grateful to the Board for your unwavering kindness and strength. Your support and compassion has meant more than words can express, giving me the space to grieve while continuing the work that matters so deeply to us all. I carry Tyson's memory with me in every part of what we do.

Thank you for walking alongside me, and for continuing to stand together as a community with courage, connection, and care.

Yours sincerely

Talia Wilson – Chairperson

Treasurer's Report

The 2024/2025 year has provided us with the opportunity to begin utilising the funds accumulated in previous years for our national conference, keenly anticipated in August 2025. This will be our most significant financial undertaking, and is proceeding within our allocated budget. We are grateful for the generous support of fundraisers and donors over many years who have made this possible. Additionally, we are also grateful for confirmation of three successful grant applications to support this conference, with the pledged funds from the Australian Government Department of Social Services National Disability Conference Initiative and pharmaceutical companies Ipsen and Regeneron to be received in the next financial year.

FOP Australia also successfully applied for a grant to support research to obtain further information regarding the needs of people living with FOP in Australia and New Zealand, to better inform future regulatory reviews of potential FOP therapies. For this purpose, a \$40,000AUD grant has been obtained through Ipsen Pharmaceuticals, with Community and Patient Preference Research (CaPPRe) being contracted after a competitive selection process to execute the project. This is our first project of this nature, and we are grateful for the opportunity to build our capacity to advocate effectively for our community.

In the context of anticipating increased grant activity and conference expense management, we have taken steps to continue to strengthen and streamline our financial management processes. Specifically:

- We successfully completed the transition process between banking providers this financial year, with closure of our previous account as planned. As described in the FY23/24 report, this transition was planned after recurring fraudulent transactions (with all funds recovered), and to improve interest accumulation and minimise bank fees.
- The board have invested a small amount (\$180) of our budget in enabling access to bookkeeping software, and established a pathway for ongoing support via Empire Bookkeeping. (Financial statements for this financial year are therefore in a slightly different format to previous years, but previous years are included for comparison).
- We have also successfully identified an appropriate option for voluntary external audit services, and anticipate undertaking the audit process through Integrated Audit Service in coming months and implementing any potential improvements identified. We anticipate that these steps will help the organisation's long term management, and help make our volunteer roles sustainable (and potentially inviting for new volunteers!)

With such a busy year in all domains, it is wonderful to again report a successful fundraising year with \$28,328.91 raised through the generous support and hard work of many fundraisers across Australia and New Zealand.

At this stage we anticipate allocating the funds raised from the FY24/25 similarly to previous years, with an emphasis on supporting research, continuing support activities (specifically our grant programs) and

allocating a small proportion to organisational sustainability and administration. This will be reviewed by the board following the completion of the conference and finalisation of conference expenses.

Thank you for your ongoing support of FOP Australia during this busy financial year – we look forward to another busy year ahead.

Lydia Scott - Treasurer

IFOPA International Presidents Council Report

The International Presidents Council (IPC) is a network of volunteers from around the world who work together to keep our community connected and informed. We meet regularly throughout the year and discuss several topics such as trial information, FOP gatherings around the world, and how we can better meet the needs of the community. Please see below for an update on some of the international activities held in FY25.

The IFOPA's annual In Pursuit of a Cure campaign was held in September 2024. The campaign raised over \$503,000USD to advance research for FOP. You can watch the launch video at this [link](#)

The IFOPA 2024 family gathering was held in Colorado in November 2024. There are several recorded sessions to view. Topics include an introduction of the IFOPA and their role over the years, care management and questions from the community, clinical trial information, the power of one presented by Dr Fred Kaplan, and navigating FOP. You can view the sessions at this link https://www.ifopa.org/2024_family_gathering

The next IFOPA family gathering will be held in Minneapolis in November 2025. After this event, family gathering will be held every 2nd year with the next one scheduled for 2027 in the Northeast region of the United States.

We are grateful for the support from the IFOPA and several clinicians from the International Clinical Council for FOP for our upcoming patient conference in August. We have 2 international doctors attending in person and 5 providing online support on a range of FOP topics. The IFOPA has provided support for the ability toolbox sessions, as well as printed materials for our community. We are thankful for this support and know their contributions will be appreciated by the community.

Resources for Support:

The IFOPA provide many services for the FOP community, see below for helpful links:

YouTube – There are a number of presentations on a range of topics at the IFOPA you tube channel

<https://www.youtube.com/@IFOPA>

Ability Toolbox – helps to empower individuals with FOP by promoting independence using tools and home adaptations. I highly recommend reading more at the link below.

https://www.ifopa.org/ability_toolbox_program

Resilient Living Program – focuses on the emotional well-being of families, including siblings, caretakers, spouses, and partners.

https://www.ifopa.org/resiliency_program

Support Resources

https://www.ifopa.org/resources_for_support

Medical treatment guidelines are available at this link, including resources on Covid-19.

https://www.ifopa.org/for_medical_professionals

I look forward to bringing you further updates from the international community.

Brooke Scott, IPC Representative

Medical Report

2024/2025 has been another year of significant milestones in FOP treatment access, particularly the recommendation by the Pharmaceutical Benefits Advisory Committee (PBAC) that palovarotene be listed for subsidised supply on Australia's Pharmaceutical Benefits Scheme (PBS). This the first time PBAC had reviewed a potential FOP treatment, and having an ultra rare disease drug recommended on first review is wonderful news. Review of ultra rare disease drugs is inherently difficult due to data issues with small populations, and the palovarotene trial data was particularly complex. Especially in that context, it was great to see PBAC publicly acknowledge in their announcement "the high and urgent clinical need for treatments for FOP". I would like to acknowledge the input of the 12 FOP families who generously contributed their personal stories to the consumer comments, which I believe was pivotal to enabling PBAC to understand this disease. Given the comparative nature of the PBAC review process, this has set us up well to advocate effectively in reviews of future FOP therapies currently undergoing trials.

As of the end the financial year, the Department of Health processes to complete the PBS listing were still ongoing. This represents a longer than expected timeframe. As such FOP Australia remain in regular contact with DoH staff and palovarotene's pharmaceutical sponsor (Ipsen) to request regular updates from both parties, and to ensure that the Minister for Health is aware of how consequential delays in treatment access can be for people living with FOP. We have been assured by all parties that progress is continuing and that PBS listing is anticipated in coming months, though a final date has not yet been confirmed. We will continue to advocate and update the community on future progress.

Working through the PBAC review and PBS listing steps has been a uniquely valuable opportunity to learn about how to effectively advocate for treatment access at all stages of the process. With several promising treatments on the horizon, this has helped us prepare for future advocacy efforts. For example:

- PBAC noted that uncertainties in modelling caused challenges in the review. Therefore, we are seeking to further characterise the needs of our local population of people living with FOP, so that better data will be available when PBAC next review an FOP treatment. This has led to a successful research grant application (supported by Ipsen) and contracting of Community and Patient Preference Research (CaPPRe) to commence this work. We look forward to inviting people with FOP and their parents to participate in this very soon!
- Chair Talia Wilson attended a roundtable meeting with Rare Voices Australia, PBAC representatives and other patient organisations in February 2025 to discuss learnings and challenges in consumer contributions to the PBAC process.

We also anticipate that an additional outcome of the PBS listing of palovarotene will be an opportunity to raise awareness of FOP amongst Australian clinicians. In combination with our national conference, this provides us with our best opportunity yet to raise awareness for potential new diagnoses, and to build local treatment expertise. To aide with this, we are deeply grateful for the support of several International Clinical Council for FOP members who have committed to travelling to Australia for our meeting and/or contributing expertise via online presentations.

Apart from our upcoming conference, other anticipated future events include outcomes from the Regeneron phase III trial of garetosmab. We do not yet know the timeframe for when this will be available, but remain in contact with Regeneron and are assured they know how keenly the FOP community is awaiting this information! Trials currently listed as active in Australia and New Zealand are Incyte's Phase II zilurgisertib PROGRESS trial (Murdoch Children's Research Institute and Starship Children's Hospital Auckland), Regeneron's Phase III garetosmab OPTIMA trial and Ipsen's Phase II fidrisertib FALKON trial (both at Royal

North Shore Hospital). I encourage you to monitor for updates at https://www.ifopa.org/ongoing_clinical_trials_in_fop, which also summarises progress in other trials including Ashibio's Phase II andecaliximab ANDECAL trial which currently only has active trial sites in the USA.

Other ongoing important research activity includes the FOP Registry (<https://www.ifopa.org/fopregistry>), which will continue to increase in impact and importance as people with FOP continue to share their information over time. Thank you to the members of FOP Australia who contribute to this vital project. Other local contributions to research include the financial contributions FOP Australia sent from FY 23/24 donations to University of Pennsylvania's Shore Lab for ongoing research to understand FOP, to the research programs of the International FOP Association (ifopa.org). We look forward to continuing to support research using the funds raised in FY 24/25, and will share details once allocations have been finalised after completion of our upcoming conference.

In addition to research news, regarding current treatment please note that the International Clinical Council for FOP released an update of their treatment guidelines in July 2024. There is a link to these at the top of every page on our fopaaustralia.org website, and further information available at www.iccfop.org.

Finally, thank you to every person with FOP, and their family and care teams, who provide input in any way to keep the global FOP research effort progressing towards a cure. Your generosity and courage has been the driver for every part of the considerable progress made in recent decades, and is the reason we can all hope for a better future for our loved ones. I look forward to sharing more updates with you next year.

Lydia Scott, Board Director / IFOPA Research Committee Member / General Medical Consultant

Acknowledgements and Contact Details

We would like to acknowledge the efforts of everyone who has supported our community over the last financial year.

Community Acknowledgements

- Australian and New Zealand FOP patients and families
- FOP Australia members
- FOP Clinicians
- International FOP Association (IFOPA)
- Oliver Collins Education Grant selection panel member: Amanda Cali
- Support Grant Program volunteers: Georgie Hyder, Dr Felicity Collins, Melissa Davis, Michelle Davis (IFOPA)
- Conference planning team volunteers Lyn Smith and Coralie Barker.
- Joyce Pettersen for merchandise stock management and postage.

Fundraiser Acknowledgements

A special thank you to volunteers who have coordinated fundraiser events:

- Coffee Club
- FOP Awareness Socks and Shoelaces
- 2025 Wildlife Calendars
- Battery Collection
- ElectraNet
- Run Melbourne
- Entertainment books
- Charity Buy
- Containers for change recycling

FOP Australia: How you can help

Spread the word on social media: follow us on Facebook, LinkedIn and Instagram. “Like” and share our posts

Newsletter: Encourage others to sign up as members online and share our quarterly newsletter with family and friends on Social Media

Membership for is \$10 per person per financial year and is free for those living with FOP or clinicians interested in learning more about FOP [Join here](#)

FOP Registry: If you or your child has FOP, please register on the FOP Connection Registry and update your data every 6 months.

Fundraising: Support our fundraising activities or even come up with your own fundraising ideas

Corporate Partnership: Become a Corporate Partner

Donate money: Direct donations through our website – all donations are tax deductible and are channelled toward our FOP community

Donate your Time: Donate your time to helping our community through leading a fund-raising event or consider joining our board

FOP Australia: Contact Us

		https://fopaustralia.org/
		info@fopaustralia.org
		https://www.facebook.com/FOPAustralia/
		https://www.linkedin.com/company/fop-australia
		https://www.instagram.com/fop_australia

Appendix 1: Financial Statements

Statement of Profit or Loss and other comprehensive income for the year ending 30th June 2025

FOP Australia

ABN 51 603 200 871

Profit and Loss

FOP Australia Ltd
For the year ended 30 June 2025

	2025
Trading Income	
Donations	13,375.71
Fundraising	11,580.39
Interest Income	3,372.81
Total Trading Income	28,328.91
Cost of Sales	
Platform fees	393.22
Total Cost of Sales	393.22
Gross Profit	27,935.69
Other Income	
Grants received	40,750.00
Total Other Income	40,750.00
Operating Expenses	
Bank Fees	95.50
Bookkeeping & Accounting costs including Xero access	180.00
Conference	28,567.50
Donation to UPenn	5,000.00
Donations to IFOPA	16,615.00
Support grant program out	1,478.00
Total Operating Expenses	51,936.00
Net Profit	16,749.69

Previous years' records for comparison:

	FOP Australia ABN 51 603 200 871 Statement of Profit or Loss and Other Comprehensive Income For the year ended 30 June 2024	
	2024	2023
	\$	\$
Fundraising	43,231	48,494
Gross Profit	43,231	48,494
IFOPA contribution	-17,497	-25,559
UPenn contribution	-5,000	-5,000
Other	-4,982	-7,699
Total overheads	-27,479	-38,258
Profit before income tax	15,752	10,236
Income tax (credit) expense		
Profit for the year	15,752	10,236
Total comprehensive income for the year	15,752	10,236

Statement of Financial Position

FOP Australia

ABN 51 603 200 871

Statement of financial position as at 30 June 2025

Balance Sheet

FOP Australia Ltd
As at 30 June 2025

30 JUNE 2025

Assets

Bank	
Community Acct...0512	5,062.49
Esaver Acct...0511	165,277.72
Total Bank	170,340.21
Total Assets	170,340.21

Net Assets

170,340.21

Equity

Current Year Earnings	16,749.69
Retained Earnings	153,590.52
Total Equity	170,340.21

Previous years' records for comparison:

FOP Australia
ABN 51 603 200 871
Statement of Financial Position
As at 30 June 2024

	2024	2023
	\$	\$
Assets		
Current assets		
Cash assets	153,590	137,838
Total current assets	153,590	137,838
Total assets	153,590	137,838
Net assets	153,590	137,838
Equity		
Retained profits	137,839	127,603
Current year profit	15,752	10,236
Total equity	153,590	137,839

Statement of Cash Flows

FOP Australia

ABN 51 603 200 871

Statement of Cash Flows for the year ended 30 June 2025

Statement of Cash Flows

FOP Australia Ltd
For the year ended 30 June 2025

2025

Operating Activities	
Receipts from customers	28,328.91
Payments to suppliers and employees	(52,329.22)
Cash receipts from other operating activities	40,750.00
Net Cash Flows from Operating Activities	16,749.69
Net Cash Flows	16,749.69
Cash and Cash Equivalents	
Cash and cash equivalents at beginning of period	153,590.52
Net change in cash for period	16,749.69
Cash and cash equivalents at end of period	170,340.21

Previous years' records for comparison:

FOP Australia
ABN 51 603 200 871
Statement of Cash Flows
For the year ended 30 June 2024

	2024	2023
	\$	\$
Cash flow from operating activities		
Receipts from customers	43,231	48,494
Payments to suppliers		-4,199
IFOPA contribution	-17,497	-25,559
UPenn contribution	-5,000	-5,000
Unapproved transactions – money returned		-3,499
Net cash provided by (used in) operating activities	15,752	10,236
Net increase (decrease) in cash held	15,752	10,236
Cash at the beginning of the year	137,839	127,603
Cash at the end of the year	153,590	137,839

Appendix 2: Notes to Financial Statements

FOP Australia

ABN 51 603 200 871

Notes to the Financial Statements for the year ended 30 June 2025

Note 1: Summary of Significant Accounting Policies

FOP Australia Ltd is a company limited by guarantee, incorporated, and domiciled in Australia. The company is registered with the Australian Charities and Not for Profits Commission and holds Deductible Gift Recipient Status.

The financial statements were authorised for issue on 29th July 2025 by the directors of the company.

Basis of preparation

The directors have prepared the financial statements on the basis that the company is a non-reporting entity because there are no users dependent on general purpose financial statements. The financial statements are therefore special purpose financial statements that have been prepared in order they meet the Collections Act 1966.

The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

The financial statements have been prepared in accordance with the mandatory Australian Accounting Standards applicable to entities reporting under the Australian Charities and Not-for-profits Act 2012 and the significant accounting policies disclosed below, which the directors have determined are appropriate to meet the needs of members. Such accounting policies are consistent with the previous period unless stated otherwise.

The financial statements, except for cash flow information have been prepared on an accruals basis and are based on historical costs unless otherwise stated in the notes. The material accounting policies that have been adopted in the preparation of the statements are as follows:

Accounting Policies

• Cash and cash equivalents

Cash and cash equivalents include cash on hand and deposits held at call with banks, other shortterm highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within short-term borrowing in current liabilities on the statement of financial position.

• Revenue and other income

Revenue is measured at the fair value of the consideration received or receivable after taking into account any trade discounts and volume rebates allowed. Interest revenue is recognized using the effective interest method which for floating rate financial assets is the rate inherent in the instrument.

Revenue recognition relating to the provision of services is determined with reference to the stage of completion of the transaction at the end of the reporting period and where the outcome of the contract can be estimated reliably. Stage of completion is determined with reference to the services performed to date as

a percentage of total anticipated services to be performed. Where the outcome cannot be estimated reliably, revenue is recognized only to the extent that related expenditure is recoverable.

Appendix 3: Directors Declaration

FOP Australia

ABN 51 603 200 871

Directors Declaration

The directors of the company declare that:

1) The financial statements and notes:

(a) Comply with accounting policies described in Note 1 to the financial statements; and

(b) Give a true and fair view of the company's financial position as at 30 June 2025 and of its performance for the year ended on that date;

2) In the directors' opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.



Talia Wilson

Chair

29th July 2025